Naafs International Health Consultancy, Netherlands
*Corresponding author: Michael AB Naafs, Naafs International Health Consultancy, Netherlands
Submission: July 02, 2018;Published: July 06, 2018
Volume1 Issue4 July 2018
After the latest failure of drug trials in Alzheimer’s disease , we have to conclude that we don’t understand the disease . In an editorial in the New England Journal of Medicine, Murphy  wrote” the field is clearly in need of innovative ideas and we are very well be nearing the end of the amyloid hypothesis rope”. Antidiabetic drugs will not be the new cure for Alzheimer’s as this research also relies heavily on the amyloid-beta-tau hypothesis . So, is this the end of “Tauism” after 15 years of failing drug trials? Frankly, the answer is yes. Research in neurodegenerative diseases will move more to genetics, epigenetics, immunology and inflammation, as is illustrated by two very recent publications.